Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00992095 · ClinicalTrials.gov registry record · NA
Bioequivalency Study of Buprenorphine Hydrochloride 8 mg Tablet Under Fasted Conditions
A NA study of Opioid-Related Disorders, sponsored by Roxane Laboratories.
- Completed
- Registry status
- NA
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT00992095: Completed NA study of Opioid-Related Disorders, sponsored by Roxane Laboratories.
NCT00992095 is a NA study of Opioid-Related Disorders that has completed, run by Roxane Laboratories. The registered enrollment target is 48 participants, below the 346-participant average among 47 other Opioid-Related Disorders trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00992095, a NA study of Opioid-Related Disorders, has completed, sponsored by Roxane Laboratories.
- COMPLETED
- Registry status
- NA
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study was to prove the bioequivalence of Buprenorphine HCl 8 mg tablet under fasted conditions.
Conditions Studied
Interventions
- DRUG buprenorphine hydrochloride
Study Locations (1)
Texas
- CEDRA Clinical Research - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2006-08 |
| Est. Completion | 2006-09 |
| Phase | NA |
What the finished NCT00992095 record still lists
NCT00992095 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 346-participant average among 47 other Opioid-Related Disorders trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Opioid-Related Disorders appearing as the primary indexed condition, and to 1 intervention - of which buprenorphine hydrochloride is the first listed.
NCT00992095 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00992095 about?
NCT00992095 is a clinical study titled "Bioequivalency Study of Buprenorphine Hydrochloride 8 mg Tablet Under Fasted Conditions". The objective of this study was to prove the bioequivalence of Buprenorphine HCl 8 mg tablet under fasted conditions.
What is the current status of trial NCT00992095?
This trial is currently completed. It is a NA study. The enrollment target is 48 participants. The study started on 2006-08. Estimated completion is 2006-09.
What conditions does trial NCT00992095 study?
This clinical trial studies the following conditions: Opioid-Related Disorders.
What interventions are being tested in trial NCT00992095?
The interventions under investigation include: buprenorphine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00992095?
This trial is sponsored by Roxane Laboratories, which has 93 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00992095 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid-Related Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00992095's enrollment target sits among peer trials
48 33rd of 47 higher than 15 of 47 other Opioid-Related Disorders trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Opioid-Related Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Developing and Evaluating a Machine-Learning Opioid Overdose Prediction & Risk-Stratification Tool in Primary Care
RECRUITING · NA
-
Developing a Smartphone Application to Support Veteran Opioid Use Disorder Treatment
RECRUITING · NA
-
OUD Smartphone Services
ACTIVE NOT RECRUITING · NA
-
Developing a Tailored Stigma Reduction Intervention to Increase Buprenorphine Prescribing
ACTIVE NOT RECRUITING · NA
-
Healthy Opioid Prescription Engagement
ACTIVE NOT RECRUITING · NA
-
Kentucky Outreach Service Kiosk (KyOSK): Reducing HIV, HCV, and Overdose Risk
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia